Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Acta Neuropathologica
Published in: Acta Neuropathologica 3/2003

01-09-2003 | Regular Paper

α-Synuclein pathology in Parkinson’s and Alzheimer’s disease brain: incidence and topographic distribution—a pilot study

Author: Kurt A. Jellinger

Published in: Acta Neuropathologica | Issue 3/2003

Login to get access

Abstract

To study the incidence and topographic distribution of α-synuclein-positive inclusions in Parkinson’s disease (PD), dementia with LB (DLB), and Alzheimer’s disease (AD), 206 brains of elderly patients, including 53 patients with clinical PD, 110 autopsy-proven AD cases, 22 with dementia with LB (DLB), 1 case with essential tremor, and 20 age-matched controls were investigated using α-synuclein immunohistochemistry. For technical reasons, the olfactory system was not studied. In all PD brains, α-synuclein-positive inclusions and neuronal losses were present in medullary and pontine nuclei, locus coeruleus, and substantia nigra, with additional lesions in amygdala (24%), allocortex (58%), cingulate area (34%), and isocortex (26.5%). All PD cases corresponded to pathology stage 4–6 suggested by Braak et al. (2003, Neurobiol Aging 24:197). In most cases of DLB, the distribution of α-synuclein pathology and neurodegeneration corresponded to stages 5 and 6 of PD pathology. The case with essential tremor and 48.2% of the AD cases showed no LB pathology; in the other AD brains α-synuclein-positive inclusions were seen in various brain areas. None of the controls showed LB pathology. Among 12 cases of incidental Lewy body disease (without clinical parkinsonian signs), 7 corresponded morphologically to PD stage 3 or 4. In further 6 AD cases, 2 with parkinsonian symptoms, considerable damage to locus coeruleus, substantia nigra, nucleus basalis and allocortex with preservation of the medullary nuclei was seen. The preliminary data largely confirm the Braak staging of brain pathology, although some of the clinical PD cases corresponded to stage 3 often considered as “preclinical”. In addition, some cases without demonstrable involvement of medullary nuclei showed extensive PD-like pathology in other brain areas, suggesting deviation from the proposed stereotypic expansion pattern and that incidental LB pathology may affect solely the locus coeruleus and substantia nigra. Striking similarity of LB pathology between DLB and PD suggests close morphological relationship between both disorders. Widespread LB lesions occurred in many sporadic AD cases without parkinsonian symptoms, the pathogenesis and clinical impact of which are unclear. The relationship between AD and PD with particular reference to synaptophysin-positive lesions needs further elucidation.
Literature
1.
American Psychiatric Association (1999) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington
2.
Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW (2002) Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 59:102–112PubMedCrossRef
3.
Arai Y, Yamazaki M, Mori O, Muramatsu H, Asano G, Katayama Y (2001) α-Synuclein-positive structures in cases with sporadic Alzheimer’s disease: morphology and its relationship to tau aggregation. Brain Res 888:287–296PubMedCrossRef
4.
Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259PubMedCrossRef
5.
Braak H, Braak E, Yilmazer D, Vos RA de, Jansen EN, Bohl J (1996) Pattern of brain destruction in Parkinson’s and Alzheimer’s diseases. J Neural Transm 103:455–490PubMedCrossRef
6.
Braak H, Braak E, Yilmazer D, Vos RA de, Jansen EN, Bohl J, Jellinger K (1994) Amygdala pathology in Parkinson’s disease. Acta Neuropathol 88:493–500PubMedCrossRef
7.
Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rüb U (2002) Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages). J Neurol 249(Suppl 3):III/1–5
8.
Braak H, Del Tredici K, Rüb U, Vos RA de, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211PubMedCrossRef
9.
Braak H, Rüb U, Braak E (2000) Neuroanatomie des Morbus Parkinson. Veränderungen des neuronalen Zytoskeletts in nur wenigen für den Krankheitsprozess empfänglichen Nervenzelltypen führen zur progredienten Zerstörung umschriebener Bereiche des limbischen und des motorischen Systems. Nervenarzt 71:459–469
10.
Braak H, Rüb U, Gai WP, Del Tredici K (2003) Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm. doi:10.​1007/​s00702-002-0808-2 (published online March 5, 2003)PubMed
11.
Braak H, Rüb U, Sandmann-Keil D, Gai WP, Vos RA de, Jansen Steur EN, Arai K, Braak E (2000) Parkinson’s disease: affection of brain stem nuclei controlling premotor and motor neurons of the somatomotor system. Acta Neuropathol 99:489–495PubMedCrossRef
12.
Brown DF, Dababo MA, Bigio EH, Risser RC, Eagan KP, Hladik CL, White CL 3rd (1998) Neuropathologic evidence that the Lewy body variant of Alzheimer disease represents coexistence of Alzheimer disease and idiopathic Parkinson disease. J Neuropathol Exp Neurol 57:39–46PubMedCrossRef
13.
Damier P, Hirsch EC, Agid Y, Graybiel AM (1999) The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson’s disease. Brain 122:1437–1448PubMedCrossRef
14.
Del Tredici K, Rüb U, De Vos RA, Bohl JR, Braak H (2002) Where does parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 61:413–426PubMed
15.
DeLucia MW, Cookson N, Dickson DW (2002) Synuclein-immunoreactive Lewy bodies are detected in the amygdala in less than 20% of Alzheimer’s disease (AD) cases. J Neuropathol Exp Neurol 61:454
16.
17.
Duda JE, Giasson BI, Mabon ME, Lee VM, Trojanowski JQ (2002) Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol 52:205–210PubMedCrossRef
18.
19.
Fearnley JM, Lees AJ (1994) Pathology of Parkinson disease. In: Calne DB (ed) Neurodegenerative diseases. Saunders, Philadelphia, pp 545–554
20.
Folstein MF, Folstein SE, McHugh PR (1975) “Mini-Mental” state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198PubMedCrossRef
21.
22.
Gai WP, Blumbergs PC, Geffen LB, Blessing WW (1992) Age-related loss of dorsal vagal neurons in Parkinson’s disease. Neurology 42:2106–2111PubMed
23.
Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56:33–39PubMedCrossRef
24.
Gertz HJ, Xuereb J, Huppert F, Brayne C, McGee MA, Paykel E, Harrington C, Mukaetova-Ladinska E, Arendt T, Wischik CM (1998) Examination of the validity of the hierarchical model of neuropathological staging in normal aging and Alzheimer’s disease. Acta Neuropathol 95:154–158PubMedCrossRef
25.
Gibb WR, Lees AJ (1989) The significance of the Lewy body in the diagnosis of idiopathic Parkinson’s disease. Neuropathol Appl Neurobiol 15:27–44PubMedCrossRef
26.
Halliday GM, Li YW, Blumbergs PC, Joh TH, Cotton RG, Howe PR, Blessing WW, Geffen LB (1990) Neuropathology of immunohistochemically identified brain stem neurons in Parkinson’s disease. Ann Neurol 27:373–385PubMedCrossRef
27.
Hamilton RL (2000) Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using α-synuclein immunohistochemistry. Brain Pathol 10:378–384PubMedCrossRef
28.
Hansen L, Salmon D, Galasko D, et al (1990) The Lewy body variant of Alzheimer’s disease: a clinical and pathologic entity. Neurology 40:1–8PubMed
29.
Harding AJ, Stimson E, Henderson JM, Halliday GM (2002) Clinical correlates of selective pathology in the amygdala of patients with Parkinson’s disease. Brain 125:2431–2445PubMedCrossRef
30.
Haroutunian V, Serby M, Purohit DP, Perl DP, Marin D, Lantz M, Mohs RC, Davis KL (2000) Contribution of Lewy body inclusions to dementia in patients with and without Alzheimer disease neuropathological conditions. Arch Neurol 57:1145–1150PubMedCrossRef
31.
32.
Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184PubMedCrossRef
33.
Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ (2002) The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125:861–870PubMedCrossRef
34.
Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D, Schmidt ML, Lee VM, Clark CM, Glosser G, Stern MB, Gollomp SM, Arnold SE (2000) α-Synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology 54:1916–1921PubMed
35.
Ince PG, Perry EK, Morris CM (1998) Dementia with Lewy bodies. A distinct non-Alzheimer dementia syndrome? Brain Pathol 8:299–324PubMedCrossRef
36.
Ishizawa T, Mattila P, Davies P, Wang D, Dickson DW (2003) Colocalization of tau and α-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol 62:389–397PubMed
37.
Jellinger K (1991) Pathology of Parkinson’s disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol 14:153–197PubMedCrossRef
38.
Jellinger KA (2001) The pathology of Parkinson’s disease. Adv Neurol 86:55–72PubMed
39.
Jellinger KA, Bancher C (1998) Neuropathology of Alzheimer’s disease: a critical update. J Neural Transm Suppl 54:77–95PubMed
40.
Jellinger KA, Mizuno Y (2003) Parkinson disease. In: Dickson DW, et al (eds) Neurodegeneration and dementias. ISN Press, Los Angeles (in press)
41.
Jellinger KA, Seppi K, Wenning GK, Poewe W (2002) Impact of coexistent Alzheimer pathology on the natural history of Parkinson’s disease. J Neural Transm 109:329–339PubMedCrossRef
42.
Jellinger KA, Seppi K, Wenning GK (2003) Neuropathologic changes in Parkinson disease with late onset of dementia. (Letter) Arch Neurol 60:452–454CrossRef
43.
Kövari E, Gold G, Herrmenn FR, Canuto A, Hof PK, Bouras G, Giannakopoulos P (2003) Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson disease. Acta Neuropathol 106:83–88PubMed
44.
Lewy F (1913) Zur pathologischen Anatomie der Paralysis agitans. Dtsch Z Nervenheilkd 50:50–55
45.
Lewy FH (1912) Paralysis agitans. Pathologische Anatomie. In: Lewandowsky M (ed) Handbuch der Neurologie. Springer, Berlin, pp 920–933
46.
Lippa CF, Fujiwara H, Mann DM, Giasson B, Baba M, Schmidt ML, Nee LE, O’Connell B, Pollen DA, St George-Hyslop P, Ghetti B, Nochlin D, Bird TD, Cairns NJ, Lee VM, Iwatsubo T, Trojanowski JQ (1998) Lewy bodies contain altered α-synuclein in brains of many familial Alzheimer’s disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 153:1365–1370PubMedCrossRef
47.
Lippa CF, Schmidt ML, Lee VM, Trojanowski JQ (1999) Antibodies to α-synuclein detect Lewy bodies in many Down’s syndrome brains with Alzheimer’s disease. Ann Neurol 45:353–357PubMedCrossRef
48.
Lowe J, Leigh PN (2002) Disorders of movement and system degenerations. In: Graham D, Lantos PL (eds) Greenfield’s neuropathology, 7th edn. Arnold, London, pp 325–430
49.
Marui W, Iseki E, Nakai T, Miura S, Kato M, Ueda K, Kosaka K (2002) Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies. J Neurol Sci 195:153–159PubMedCrossRef
50.
Mattila PM, Rinne JO, Helenius H, Dickson DW, Roytta M (2000) α-Synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson’s disease. Acta Neuropathol 100:285–290PubMedCrossRef
51.
McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, Vos RA de, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113–1124PubMed
52.
Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, Belle G van, Berg L (1991) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41:479–486PubMed
53.
Nieuwenhuys R (1996) The greater limbic system, the emotional motor system and the brain. Prog Brain Res 107:551–580PubMedCrossRef
54.
Olszewski J, Baxter D (1982) Cytoarchitecture of the human brain stem, 2nd edn. Karger, Basel
55.
Parkkinen L, Soininen H, Alafuzoff I (2003) Regional distribution of α-synuclein pathology in unimpaired aging and Alzheimer disease. J Neuropathol Exp Neurol 62:363–367PubMed
56.
Pearce RK, Hawkes CH, Daniel SE (1995) The anterior olfactory nucleus in Parkinson’s disease. Mov Disord 10:283–287PubMedCrossRef
57.
Perl DP, Purohit DP, Haroutunian V (1997) Clinicopathologic correlations of the Alzheimer disease staging system introduced by Braak and Braak. J Neuropathol Exp Neurol 56:577CrossRef
58.
Perry RH, Irving D, Tomlinson BE (1990) Lewy body prevalence in the aging brain: relationship to neuropsychiatric disorders, Alzheimer-type pathology and catecholaminergic nuclei. J Neurol Sci 100:223–233PubMedCrossRef
59.
Schmidt ML, Martin JA, Lee VM, Trojanowski JQ (1996) Convergence of Lewy bodies and neurofibrillary tangles in amygdala neurons of Alzheimer’s disease and Lewy body disorders. Acta Neuropathol 91:475–481PubMedCrossRef
60.
Trembath Y, Rosenberg C, Ervin JF, Schmechel DE, Gaskell P, Pericak-Vance M, Vance J, Hulette CM (2003) Lewy body pathology is a frequent co-pathology in familial Alzheimer’s disease. Acta Neuropathol 105:484–488PubMed
61.
Wakabayashi K, Toyoshima Y, Awamori K, Anezaki T, Yoshimoto M, Tsuji S, Takahashi H (1999) Restricted occurrence of Lewy bodies in the dorsal vagal nucleus in a patient with late-onset parkinsonism. J Neurol Sci 165:188–191PubMedCrossRef
62.
Mikolaenko L, Kwan CH, O’Brien R, Petnikov O, Troncoso JC (2003) Abstr. 6th International Conference AD|PD 2003; Seville, Spain, 8–12 May 2003; p 133
Metadata
Title
α-Synuclein pathology in Parkinson’s and Alzheimer’s disease brain: incidence and topographic distribution—a pilot study
Author
Kurt A. Jellinger
Publication date
01-09-2003
Publisher
Springer-Verlag
Published in
Acta Neuropathologica / Issue 3/2003
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI
https://doi.org/10.1007/s00401-003-0725-y

Other articles of this Issue 3/2003

Acta Neuropathologica 3/2003 Go to the issue

Regular Paper

Tau and 14-3-3 in glial cytoplasmic inclusions of multiple system atrophy

Regular Paper

Familial British dementia: colocalization of furin and ABri amyloid

Regular Paper

Encephalopathy in megacystis-microcolon-intestinal hypoperistalsis syndrome patients on long-term total parenteral nutrition possibly due to selenium deficiency

Regular Paper

Expression and release of CD14 in astrocytic brain tumors

Regular Paper

MELAS: clinical phenotype and morphological brain abnormalities

Regular Paper

The effect of combined neurolytic blocking agent 5% phenol-glycerol in rat sciatic nerve